The first pneumococcal conjugate vaccine (PCV) was licensed more than 25 years ago in the USA and Europe, but its marketing authorisation was based on efficacy studies using a 3+1 dosing regimen, ...

Public health authorities outline who needs which vaccines, organized by age and other key variables—important information ...

Besides all serotypes covered by the Pfizer shot, VAX-31 contains 11 additional serotypes ... designed to prevent more than 95% of invasive pneumococcal disease circulating in adults 50 and ...

Healthcare providers, public health officials and policymakers need to develop a greater understanding of the serious health impact of pneumococcal disease in elderly adults. In addition to ...

For all 11 incremental serotypes unique to VAX-31 ... The FDA recently approved Merck & Co Inc's (NYSE: MRK) Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) as the first pneumococcal ...

Beijing: A 30-year-old Chinese man died from organ failure after working 104 days straight with just one day off. A court ...

Hearing loss affects millions of people, but hearing aids have been expensive and sales have been dominated by a few ...

Healthy children get a 3 + 0 dose schedule, children at risk do get fourth dose of pneumococcal conjugate vaccine (PCV) at 12 months of age, and a booster dose of 23-valent polysaccharide vaccine ...

Vaxcyte’s shot covers an additional 11 strains than Prevnar 20 ... indicates Wall Street sees it as a potential competitor to pneumococcal vaccines from Pfizer, Merck & Co. and GSK.

Pfizer's recent financial performance shows 14% YoY operational growth excluding COVID sales. Check out more on PFE stock ...

While economic data may be scarce, every data point gives a new angle to the ever-uncertain economic conditions in the US.

Also Read: Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots – Analyst ... immune responses compared to PCV20. For all 11 incremental serotypes unique to VAX-31 ...